AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,509 AI briefs of material SEC Form 8-K filings by 4,787 companies: 2,123 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,509every one kept
Companies4,787with at least one brief
Recent filings2,123filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.
- Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
- R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
- G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
- Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.
Read the filing on SEC.gov ↗
Spruce Biosciences reported a third-quarter 2026 net loss of $24.0 million, or $(8.51) per share, up from $8.2 million, or $(14.58) per share, a year earlier. The company also separated its CRHX-101 program into a new subsidiary, Adrenyx Biosciences, and plans to distribute Adrenyx shares to Spruce stockholders, a step its board has not yet approved.
- Q3 2026 net loss was $24.0 million, or $(8.51) per share, versus $8.2 million, or $(14.58) per share, in Q3 2025; R&D expenses were $18.1 million.
- Cash and cash equivalents were $87.7 million at September 30, 2026, up from $48.9 million at December 31, 2025, which the company says will fund operations and debt obligations into the second half of 2027.
- The Distribution of Adrenyx stock is expected in the first half of 2027, but Spruce's board has not yet approved it or set a record date.
- Under an amended Avenue loan agreement dated November 6, 2026, up to $15.0 million of Tranche 2 may be drawn between January 1, 2027 and March 31, 2027.
Read the filing on SEC.gov ↗
Whitehawk Therapeutics reported a third-quarter 2026 net loss of $21.2 million, up from $17.7 million a year earlier, as research and development expenses rose to $18.1 million from $14.3 million. The company reported no revenue in the quarter and said its cash, cash equivalents and short-term investments of $169.7 million should fund operations into the second half of 2028.
- Q3 2026 net loss was $21.2 million, compared with $17.7 million in Q3 2025.
- Research and development expenses were $18.1 million, compared with $14.3 million a year earlier.
- Cash, cash equivalents and short-term investments were $169.7 million as of September 30, 2026, versus $145.7 million at December 31, 2025.
- The Phase 1 trial of HWK-206 began in the U.S., and the FDA granted it Fast Track designation; initial Phase 1 data from HWK-007 and HWK-016 are expected in the first half of 2027.
Read the filing on SEC.gov ↗
Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, up from $14.3 million, or $0.08 per share, a year earlier. Higher research and development and general and administrative spending drove the increase, and cash and marketable securities fell to $163 million, which the company says will fund operations into 2028.
- Q3 2026 net loss was $27.2 million ($0.15 per share) versus $14.3 million ($0.08 per share) in Q3 2025.
- Nine-month net loss was $70.6 million ($0.38 per share) versus $50.8 million ($0.34 per share) a year earlier.
- Cash and marketable securities were $163 million at September 30, 2026, down from $209 million at December 31, 2025, with $48 million used in operating activities.
Read the filing on SEC.gov ↗
Bicara Therapeutics reported a third-quarter 2026 net loss of $71.2 million, nearly double the $36.3 million loss a year earlier, as research and development and general and administrative costs rose for its pivotal trial and commercial preparation. The company said its $442.3 million in cash and marketable securities should fund operations into the first half of 2029, and it reiterated that topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
- Net loss was $71.2 million for the quarter ended September 30, 2026, versus $36.3 million a year earlier.
- Research and development expenses rose to $56.5 million from $33.0 million; general and administrative expenses rose to $19.2 million from $7.7 million.
- Cash, cash equivalents and marketable securities were $442.3 million at September 30, 2026, which the company expects to fund operations into the first half of 2029.
- Topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Read the filing on SEC.gov ↗
Popular, Inc. filed an 8-K updating its third-quarter 2026 results after a commercial borrower in the quick service restaurant industry substantially ceased operations and filed for Chapter 11 bankruptcy following the earnings release. The company recognized an additional $38 million provision for credit losses, lowering quarterly net income to $242.4 million from $266.3 million and diluted EPS to $3.83 from $4.21, and it raised its 2026 net charge-off guidance to 90 bps to 95 bps from 80 bps to 90 bps.
- Q3 2026 net income of $242.4 million, down $23.9 million from the $266.3 million in the original earnings release.
- Diluted EPS of $3.83 versus $4.21 as originally issued; up from $3.14 in the same quarter of 2025.
- The company expects an additional fourth-quarter 2026 charge-off on the same relationship.
- 2026 net charge-off guidance raised to 90 bps to 95 bps from 80 bps to 90 bps; Common Equity Tier 1 ratio of 16.01%, down 5 bps.
Read the filing on SEC.gov ↗
Tango Therapeutics reported a third quarter 2026 net loss of $68.4 million, or $0.39 per share, compared with net income of $15.9 million, or $0.13 per diluted share, in the same quarter of 2025. Collaboration revenue fell to $0 from $53.8 million after the Gilead collaboration concluded research activities in August 2025, while research and development and general and administrative spending both rose.
- Collaboration revenue was $0 in Q3 2026, versus $53.8 million in Q3 2025.
- R&D expenses rose to $48.9 million from $30.8 million; G&A expenses rose to $29.2 million from $8.9 million.
- Cash, cash equivalents and marketable securities totaled $977.5 million as of September 30, 2026.
- Tango intends to initiate a Phase 3 study of vopimetostat plus daraxonrasib in front-line pancreatic cancer in the first half of 2027.
Read the filing on SEC.gov ↗
Ocular Therapeutix reported third quarter 2026 results with total net revenue of $12.9 million, down from $14.5 million a year earlier, and a net loss of $94.8 million, or $(0.42) per share, versus a net loss of $69.4 million, or $(0.38) per share, in the prior-year quarter. Research and development expenses rose to $74.8 million from $52.4 million, and the company said it had $530.6 million in cash as of September 30, 2026, with runway expected into 2028.
- Net revenue was $12.9 million for Q3 2026, compared with $14.5 million for Q3 2025.
- Net loss was $(94.8) million, or $(0.42) per share, versus $(69.4) million, or $(0.38) per share, a year earlier.
- R&D expenses were $74.8 million versus $52.4 million, reflecting faster HELIOS-3 and SOL-X enrollment and higher headcount.
- Cash and cash equivalents were $530.6 million as of September 30, 2026; the company expects this to support operations into 2028.
Read the filing on SEC.gov ↗
Aura Biosciences reported third quarter 2026 results, with a net loss of $32.1 million, up from $26.1 million a year earlier. The company said a $4.5 million restructuring charge, tied to its reorganization around its ocular oncology portfolio, contributed to higher general and administrative expenses, and it reiterated that its cash is expected to last into the first half of 2029.
- Net loss of $32.1 million for the quarter ended September 30, 2026, versus $26.1 million a year earlier; loss per share was $0.29, versus $0.40.
- General and administrative expenses rose to $10.3 million from $5.7 million, driven mainly by restructuring charges of approximately $4.5 million.
- Research and development expenses rose to $24.7 million from $22.2 million, tied to the Phase 3 CoMpass trial.
- Cash, cash equivalents and marketable securities totaled $297.2 million as of September 30, 2026.
Read the filing on SEC.gov ↗
Virtus Investment Partners reported third-quarter 2026 results for the period ended September 30, 2026, with GAAP revenue of $197.6 million, down 9% from a year earlier, and diluted EPS of $3.26 versus $4.65. Assets under management fell 16% year over year to $141.4 billion, with net outflows of $6.1 billion, which weighs on future fee revenue for shareholders.
- GAAP diluted EPS was $3.26 versus $4.65 a year earlier and $6.68 in the prior quarter; adjusted diluted EPS was $5.86 versus $7.35 a year earlier.
- Revenue was $197.6 million, down 9% from $216.4 million a year earlier and down 2% from $201.4 million in the prior quarter.
- Ending assets under management were $141.4 billion, down from $169.3 billion a year earlier, with net outflows of $6.1 billion.
- The company repurchased 64,666 shares for $10.0 million and raised its quarterly dividend 2% to $2.45 per share.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.